Psychopharmacology and Psychiatry Updates
Psychopharmacology Institute
Show overview
Psychopharmacology and Psychiatry Updates has been publishing since 2024, and across the 2 years since has built a catalogue of 106 episodes. That works out to roughly 20 hours of audio in total. Releases follow a weekly cadence.
Episodes typically run ten to twenty minutes — most land between 10 min and 14 min — and the run-time is fairly consistent across the catalogue. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Health & Fitness show.
The show is actively publishing — the most recent episode landed 5 days ago, with 27 episodes already out so far this year. The busiest year was 2025, with 73 episodes published. Published by Psychopharmacology Institute.
From the publisher
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
Latest Episodes
View all 106 episodesRethinking Haloperidol's Cardiac Risk
Bipolar Disorder, Lithium, and Pregnancy: What the Evidence Says
Clozapine Monitoring: New Guidelines for the Post-REMS Era
Prescribing Through Pregnancy: Dosing, Levels, and Relapse Risk
Bright Light Therapy for Bipolar Depression
Lithium: Managing Cosmetic and Sexual Side Effects
KarXT: A New Era in Antipsychotics?
In this episode, we explore KarXT, a newly FDA-approved antipsychotic with a groundbreaking cholinergic mechanism, through the lens of a single powerful metric: the Number Needed to Treat. Could an NNT of 5 change how you approach treatment-resistant schizophrenia? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 80 How Effective Is KarXT (Xanomeline-Trospium) for Schizophrenia? NNT and NNH Explained
Lithium: GI and Weight Side Effect Management
In this episode, we explore how to keep your patients on lithium by getting ahead of two of its most common challenges — weight gain and gastrointestinal side effects. Dr. David Osser from Harvard Medical School shares practical, proactive strategies to anticipate, prevent, and manage these issues before they drive your patients away from a medication that could truly change their lives. Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: Lithium: How to Manage Dosage and Side Effects How to Mitigate Weight Gain and Gastrointestinal Side Effects of Lithium
Beyond Weight Loss: Can Semaglutide Treat Alcohol Use Disorder?
In this episode, we explore a surprising new contender in the fight against alcohol use disorder — semaglutide. Could the blockbuster weight-loss drug also curb heavy drinking? We examine the first randomized controlled trial testing this GLP-1 receptor agonist specifically for AUD. Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 79 Semaglutide for Alcohol Use Disorder: New RCT Data
Managing Lithium's Renal Risks: Evidence-Based Strategies
In this episode, we explore lithium's renal side effects with Dr. David Osser from Harvard Medical School. How can we keep patients safe while using this highly effective medication? Discover the real risk numbers, prevention strategies, and evidence-based monitoring approaches that protect kidney function long-term. Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CMEs: Lithium: How to Manage Dosage and Side Effects Managing Renal Side Effects of Lithium Therapy
Cariprazine for Bipolar Illness in the Elderly: What the Data Show
In this episode, we explore cariprazine's efficacy and safety in older adults with bipolar I disorder. Does age change how we should dose this medication? Discover evidence-based insights on treating both depression and mania in elderly patients, plus critical pearls on monitoring for akathisia. Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 79 Cariprazine Dosing for Bipolar Disorder In Older Adults
Ep 441Lithium Essentials: Monitoring, Drug Interactions, and Safety
In this episode, we explore essential baseline testing, monitoring protocols, and optimal dosing strategies for lithium with Dr. David Osser from Harvard Medical School. Why does giving lithium once daily at night actually protect the kidneys better than divided doses? Discover evidence-based approaches that could transform your lithium prescribing practice. Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: An Update on Bipolar Mania Algorithm Diagnosing Bipolar Mania and Comorbid Disorders
Ep 439ADHD Stimulants: Clinical Safeguards Against Misuse and Diversion
In this episode, we explore the delicate balance of prescribing stimulants for adult ADHD when abuse potential is a concern. How do you distinguish between performance-driven misuse and recreational abuse? Dr. Bukstein shares essential red flags, safety precautions, and strategies to protect both patients and prescribers. Faculty: Oscar G. Bukstein, M.D., M.P.H. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Mastering Adult ADHD: A Comprehensive Clinical Guide Stimulants: Clinical Considerations, Preventing Abuse, and Red Flags
Staying Well: LAIs vs. Oral Medications in Cannabis-Induced Psychosis
In this episode, we explore groundbreaking research on treating cannabis-induced psychosis with antipsychotic medications. Which formulations cut hospitalization rates by 75%? And why do some commonly prescribed antipsychotics show no effectiveness at all in preventing future psychotic episodes? Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 78 Cannabis-Induced Psychosis: Which Antipsychotics Best Prevent Hospitalization?
Adult ADHD: Optimizing Stimulant Therapy
In this episode, we explore stimulant medications for adult ADHD with Dr. Oscar Bukstein. Why have amphetamines overtaken methylphenidate as the most prescribed option? Discover how to match formulation duration to patient needs, navigate cardiovascular risks, and monitor treatment effectively for optimal outcomes in adult ADHD management. Faculty: Oscar G. Bukstein, M.D., M.P.H. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Mastering Adult ADHD: A Comprehensive Clinical Guide Pharmacologic Treatments for Adult ADHD: Focus on Stimulants
Semaglutide for Clozapine-Induced Weight Gain: The COaST Trial
In this episode, we explore the groundbreaking COaST trial examining semaglutide for clozapine-induced weight gain in schizophrenia patients. Could GLP-1 agonists finally offer a real solution to one of psychiatry's most frustrating paradoxes—when the medication that saves lives simultaneously shortens them? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 78 Does Semaglutide Reverse Clozapine-Induced Weight Gain in Schizophrenia? Results from the COaST Trial
Beyond Stimulants: Tailoring ADHD Treatment to Comorbidities
In this episode, we explore the treatment algorithm for adult ADHD with Dr. Oscar Bukstein from Harvard Medical School. Should you start with stimulants or non-stimulants when substance use disorder complicates the picture? Discover how comorbidities like depression and anxiety reshape your medication selection strategy for optimal patient outcomes. Faculty: Oscar G. Bukstein, M.D., M.P.H Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Mastering Adult ADHD: A Comprehensive Clinical Guide Treatment Algorithm for Adult ADHD
Beyond Standard Treatment: Exploring Pramipexole in Bipolar Depression
In this episode, we explore pramipexole—a Parkinson's medication—as a promising add-on treatment for treatment-resistant bipolar depression. Could a dopamine agonist be the unexpected solution when standard mood stabilizers and antipsychotics fail? We examine the PAX-BD trial's findings, safety concerns, and practical clinical applications. Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 78 Treatment-Resistant Bipolar Depression: Is Adjunctive Pramipexole An Option?
SERT Gene Testing: Separating Hype from Evidence
In this episode, we explore the controversial role of SERT gene testing in predicting SSRI response with Dr. Chris Aiken. Can genetic testing really tell us which patients will respond to antidepressants, or are we putting too much faith in pharmacogenetic promises that lack solid evidence? Faculty: Chris Aiken, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: The Role of Genetic Testing in Psychiatry SERT Gene and SSRI Response: Is It Clinically Useful?
The SSRI-Anticoagulant Interaction: Evidence-Based Prescribing Strategies
In this episode, we explore a critical drug interaction: SSRIs combined with anticoagulants increase major bleeding risk by 35-47%. Should age and sex change our prescribing decisions? We break down the evidence from nearly 100,000 patients and discuss safer antidepressant alternatives for high-risk individuals. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 77 Do SSRIs Increase Major Bleeding Risk with Oral Anticoagulants?